Neurocrine Biosciences | NBIX - Stock


Neurocrine Biosciences reported $66.1M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Cytokinetics USD 807K 427K Sep/2026
Exelixis USD 29.87M 1.14M Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
Halozyme Therapeutics USD 132.61M 4.52M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Repligen USD 182.2M 4.4M Sep/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Teva Pharmaceutical Industries USD 3.17B 48M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026